ADULTS & ADOLESCENTS AGED 12+ YEARS

Visible changes in the esophagus were observed at Week 24.^3,a

• Part A: 49% reduction (-3.2 points) from baseline with DUPIXENT (n=42) vs 5% reduction (-0.3 points) with placebo (n=39)
• Part B: 66% reduction (-4.5 points) from baseline with DUPIXENT (n=80) vs 8% reduction (-0.6 points) with placebo (n=79)

EREFS total score was reduced at Week 52 with continued weekly DUPIXENT treatment.^3,a

• Part A-C: 63% reduction (-4.1 points) from baseline after 52 weeks of treatment with DUPIXENT (n=35) and 65% reduction (-3.9 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=30)
• Part B-C: 77% reduction (-5.3 points) from baseline after 52 weeks of treatment with DUPIXENT (n=63) and 76% reduction (-6.1 points) from baseline after switching to DUPIXENT from placebo at Week 24 (n=37)

Extended active treatment period, results are descriptive at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

^aSecondary endpoint at Weeks 24 and 52. Results are descriptive; thresholds for clinically meaningful changes in EREFS scores have not been established. Additionally, in Part B this endpoint was ordered after the point at which hierarchical testing procedure failed.

CHILDREN AGED 1-11 YEARS

DUPIXENT significantly improved the appearance of the esophagus at Week 16.^1,3,b

• EoE KIDS-Part A: 52% reduction (-3.6 points) from baseline with DUPIXENT (n=30) vs 0% worsening (0 points) with placebo (n=25) (P<0.0001)

EREFS total score was reduced at Week 52 with continued DUPIXENT treatment.^3,b

• EoE KIDS-Part B: 71% reduction (-4.9 points) from baseline with DUPIXENT (n=26) and 45% reduction (-3.3 points) from baseline after switching to DUPIXENT from placebo at Week 16 (n=13)

Thresholds for clinically meaningful changes in EREFS scores have not been established. Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

^aSecondary endpoint at Weeks 16 and 52.³

EREFS is an endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and strictures. Each feature is graded on its severity and is assigned an associated value. The EREFS total score (range: 0 to 18) is the composite value of the proximal and distal esophageal regions with each region scored from 0 to 9.^4-8

A higher score indicates greater disease severity.³